Ms Contin (Morphine Sulfate)

Morphine sulfate binds to μ‑opioid receptors in the brain and spinal cord, inhibiting the transmission of pain signals. This receptor activation reduces the perception of pain and increases the pain threshold, producing analgesia that lasts for several hours with the extended‑release formulation.

The dose of Ms Contin is individualized by the prescribing clinician. Factors such as the intensity of pain, prior opioid exposure, patient age, renal and hepatic function, and concurrent medications guide the selection of an appropriate dose and dosing interval.

Safety data for morphine sulfate in pregnancy and lactation are limited. Because opioids can cross the placenta and enter breast milk, Ms Contin should only be used during pregnancy or while breastfeeding if the potential benefit justifies the potential risk and after thorough discussion with a healthcare professional.

To request Ms Contin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Ms Contin provides a controlled, extended‑release delivery of morphine over 12‑24 hours, reducing the need for frequent dosing compared with immediate‑release morphine, which peaks quickly and requires multiple daily doses. The extended‑release form offers more stable plasma concentrations, which can improve pain control and convenience for chronic pain management.

Ms Contin tablets should be stored at ambient temperature, below 25 °C, in their original container to protect them from moisture and light. Keep the product out of reach of children and do not use tablets that are discolored, broken or past their expiration date.

Ms Contin is taken orally as a whole tablet; it must be swallowed whole with water and not chewed, crushed, or split. The extended‑release matrix is designed to release morphine slowly, and altering the tablet can lead to rapid release and increased risk of overdose.

The most serious risks associated with Ms Contin include respiratory depression, severe hypotension, profound sedation, opioid dependence or addiction, and rare allergic reactions such as anaphylaxis. Patients and caregivers should be alert for shallow breathing, extreme drowsiness, fainting, or signs of an allergic response and seek immediate medical attention if they occur.

Ms Contin should be avoided in individuals with known hypersensitivity to morphine or any component of the tablet, severe respiratory depression, acute asthma attacks, paralytic ileus, or uncontrolled severe head injury. It is also contraindicated in patients taking MAO inhibitors within 14 days or those with significant hepatic or renal impairment without dose adjustment.